SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > SQI's Covid-19 Antibody test is a game changer

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Feb 02, 2021 3:22pm

174 Views

Post# 32449269

RE:RE:RE:SQI's Covid-19 Antibody test is a game changer

bhikku2 wrote: This is my favourite story and I believe the one with the best potential in my portfolio right now.

The investor presentation they just updated estimates FDA/EUA approval of RALI-Dx and RALI-fast in Q1 2021, and for the at home COVID testing in Q4-2020/Q1-2021. So, it sounds like the at home test FDA EUA approval should be imminent, with the RALI testing soon to follow. I'm looking forward to seeing the news! I'm a little surprised they didn't remove the Q4-2020 reference when they updated the deck.

I was surprised by them overlooking that Q4-2020 reference as well. The developemt progress arrow seems inconsistent with the "at home" test being the first up for FDA approval.

In any event it all seems to be happening Q1, and Page 5 revenue potential has me excited, once the market more fully absorbs the opportunity.

Bring on the